Literature DB >> 25355317

Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer disease.

Ian Diner1, Chadwick M Hales2, Isaac Bishof1, Lake Rabenold1, Duc M Duong1, Hong Yi3, Oskar Laur4, Marla Gearing5, Juan Troncoso6, Madhav Thambisetty7, James J Lah2, Allan I Levey2, Nicholas T Seyfried8.   

Abstract

Recent evidence indicates that U1-70K and other U1 small nuclear ribonucleoproteins are Sarkosyl-insoluble and associate with Tau neurofibrillary tangles selectively in Alzheimer disease (AD). Currently, the mechanisms underlying the conversion of soluble nuclear U1 small nuclear ribonucleoproteins into insoluble cytoplasmic aggregates remain elusive. Based on the biochemical and subcellular distribution properties of U1-70K in AD, we hypothesized that aggregated U1-70K itself or other biopolymers (e.g. proteins or nucleic acids) interact with and sequester natively folded soluble U1-70K into insoluble aggregates. Here, we demonstrate that total homogenates from AD brain induce soluble U1-70K from control brain or recombinant U1-70K to become Sarkosyl-insoluble. This effect was not dependent on RNA and did not correlate with detergent-insoluble Tau levels as AD homogenates with reduced levels of these components were still capable of inducing U1-70K aggregation. In contrast, proteinase K-treated AD homogenates and Sarkosyl-soluble AD fractions were unable to induce U1-70K aggregation, indicating that aggregated proteins in AD brain are responsible for inducing soluble U1-70K aggregation. It was determined that the C terminus of U1-70K, which harbors two disordered low complexity (LC) domains, is necessary for U1-70K aggregation. Moreover, both LC1 and LC2 domains were sufficient for aggregation. Finally, protein cross-linking and mass spectrometry studies demonstrated that a U1-70K fragment harboring the LC1 domain directly interacts with aggregated U1-70K in AD brain. Our results support a hypothesis that aberrant forms of U1-70K in AD can directly sequester soluble forms of U1-70K into insoluble aggregates.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Neurodegenerative Disease; Protein Aggregation; RNA; Spliceosome; Tau Protein (Tau)

Mesh:

Substances:

Year:  2014        PMID: 25355317      PMCID: PMC4271217          DOI: 10.1074/jbc.M114.562959

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA).

Authors:  Richard J O'Brien; Susan M Resnick; Alan B Zonderman; Luigi Ferrucci; Barbara J Crain; Olga Pletnikova; Gay Rudow; Diego Iacono; Miguel A Riudavets; Ira Driscoll; Donald L Price; Lee J Martin; Juan C Troncoso
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

2.  Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.

Authors:  D W Dickson; C Bergeron; S S Chin; C Duyckaerts; D Horoupian; K Ikeda; K Jellinger; P L Lantos; C F Lippa; S S Mirra; M Tabaton; J P Vonsattel; K Wakabayashi; I Litvan
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

3.  Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration.

Authors:  Jeremy H Herskowitz; Nicholas T Seyfried; Duc M Duong; Qiangwei Xia; Howard D Rees; Marla Gearing; Junmin Peng; James J Lah; Allan I Levey
Journal:  J Proteome Res       Date:  2010-10-22       Impact factor: 4.466

4.  A novel procedure for pre-embedding double immunogold-silver labeling at the ultrastructural level.

Authors:  H Yi; J Leunissen; G Shi; C Gutekunst; S Hersch
Journal:  J Histochem Cytochem       Date:  2001-03       Impact factor: 2.479

Review 5.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

6.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

Review 7.  Protein aggregation and neurodegenerative disease.

Authors:  Christopher A Ross; Michelle A Poirier
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

Review 8.  The spliceosome: the most complex macromolecular machine in the cell?

Authors:  Timothy W Nilsen
Journal:  Bioessays       Date:  2003-12       Impact factor: 4.345

9.  Vesicular localization and activity-dependent trafficking of presynaptic choline transporters.

Authors:  Shawn M Ferguson; Valentina Savchenko; Subbu Apparsundaram; Melissa Zwick; Jane Wright; Craig J Heilman; Hong Yi; Allan I Levey; Randy D Blakely
Journal:  J Neurosci       Date:  2003-10-29       Impact factor: 6.167

Review 10.  Toxic proteins in neurodegenerative disease.

Authors:  J Paul Taylor; John Hardy; Kenneth H Fischbeck
Journal:  Science       Date:  2002-06-14       Impact factor: 47.728

View more
  18 in total

1.  RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease.

Authors:  Isaac Bishof; Eric B Dammer; Duc M Duong; Sean R Kundinger; Marla Gearing; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  J Biol Chem       Date:  2018-05-25       Impact factor: 5.157

2.  Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease.

Authors:  Measho H Abreha; Eric B Dammer; Lingyan Ping; Tian Zhang; Duc M Duong; Marla Gearing; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  Proteomics       Date:  2018-10       Impact factor: 3.984

3.  A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease.

Authors:  Nicholas T Seyfried; Eric B Dammer; Vivek Swarup; Divya Nandakumar; Duc M Duong; Luming Yin; Qiudong Deng; Tram Nguyen; Chadwick M Hales; Thomas Wingo; Jonathan Glass; Marla Gearing; Madhav Thambisetty; Juan C Troncoso; Daniel H Geschwind; James J Lah; Allan I Levey
Journal:  Cell Syst       Date:  2016-12-15       Impact factor: 10.304

4.  Characterization of Detergent Insoluble Proteome in Chronic Traumatic Encephalopathy.

Authors:  Jonathan D Cherry; Ahmad Zeineddin; Eric B Dammer; James A Webster; Duc Duong; Nicholas T Seyfried; Allan I Levey; Victor E Alvarez; Bertrand R Huber; Thor D Stein; Patrick T Kiernan; Ann C McKee; James J Lah; Chadwick M Hales
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

Review 5.  mRNP assembly, axonal transport, and local translation in neurodegenerative diseases.

Authors:  Bilal Khalil; Dmytro Morderer; Phillip L Price; Feilin Liu; Wilfried Rossoll
Journal:  Brain Res       Date:  2018-02-17       Impact factor: 3.252

6.  Distinct role of 5'UTR sequences in dendritic trafficking of BDNF mRNA: additional mechanisms for the BDNF splice variants spatial code.

Authors:  Andrea Colliva; Enrico Tongiorgi
Journal:  Mol Brain       Date:  2021-01-12       Impact factor: 4.041

7.  Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.

Authors:  Chadwick M Hales; Eric B Dammer; Qiudong Deng; Duc M Duong; Marla Gearing; Juan C Troncoso; Madhav Thambisetty; James J Lah; Joshua M Shulman; Allan I Levey; Nicholas T Seyfried
Journal:  Proteomics       Date:  2016-12       Impact factor: 3.984

8.  Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain.

Authors:  Ian Diner; Tram Nguyen; Nicholas T Seyfried
Journal:  J Vis Exp       Date:  2017-10-24       Impact factor: 1.355

Review 9.  Combating deleterious phase transitions in neurodegenerative disease.

Authors:  April L Darling; James Shorter
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-02-05       Impact factor: 4.739

10.  Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  Erik G Gentry; Benjamin W Henderson; Andrew E Arrant; Marla Gearing; Yangbo Feng; Nicole C Riddle; Jeremy H Herskowitz
Journal:  J Neurosci       Date:  2016-01-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.